Key Takeaways
- CBG (cannabigerol) is technically the precursor to all other cannabinoids -- THC, CBD, and CBC all start as CBGA before being converted -- which is why it's often called the "mother cannabinoid"
- Unlike most cannabinoids, CBG interacts with multiple receptor systems beyond CB1 and CB2, including serotonin (5-HT1A) and alpha-2 adrenoceptors, giving it a broader pharmacological profile than CBD
- The first double-blind, placebo-controlled human trial on CBG was published in 2024: 20mg of oral CBG significantly reduced anxiety and stress in healthy adults, without causing intoxication or cognitive impairment
- Preclinical evidence suggests potential in inflammatory bowel disease, glaucoma, and antibacterial applications (including against MRSA) -- but these findings remain unvalidated in human trials
- CBG is more expensive to produce than CBD because it's found in very low concentrations in mature cannabis plants, requiring either earlier harvests or selectively bred high-CBG cultivars
CBD's rapid mainstream adoption over the past decade opened a question the industry has been trying to answer ever since: what's next? CBN, CBC, and THCV have all had their moment. But CBG -- cannabigerol -- has probably the strongest scientific case of any of them for being more than just a marketing pivot.
The reason goes back to plant chemistry. All cannabinoids start as CBGA (cannabigerolic acid), the acidic precursor form of CBG. As a cannabis plant matures, enzymes convert CBGA into THCA, CBDA, and CBCA -- the precursors to THC, CBD, and CBC -- leaving very little CBG remaining in the finished plant. Typically less than 1% of the dry weight of a mature cannabis plant is CBG, compared to 20-30% for THC or CBD in high-potency cultivars. This is why CBG products tend to cost more: producing meaningful quantities requires either harvesting plants earlier (before the conversion enzymes have done their work) or cultivating specially-bred high-CBG strains.
This botanical detail matters for evaluating CBG claims, because a compound that the plant produces primarily as an intermediate -- and then converts into everything else -- is chemically interesting in ways that pure marketing isn't.
Most cannabinoids are primarily defined by how they interact with CB1 and CB2 receptors. CBG does interact with both -- as a partial agonist at CB1 and CB2, without the intoxicating effect of THC -- but it also has meaningful activity at several other receptor targets.
A comprehensive 2024 review (Li et al., 2024, Molecules) identified CBG's key interaction points: beyond CB1 and CB2, CBG shows activity at 5-HT1A serotonin receptors (the same receptor implicated in anxiety and mood regulation and targeted by some antidepressants), alpha-2 adrenoceptors (involved in blood pressure regulation and alertness), and TRPV channels (transient receptor potential channels involved in pain signaling and inflammation). This multi-target profile is part of why researchers consider CBG pharmacologically distinct from CBD, even though both are non-intoxicating.
The alpha-2 adrenoceptor activity is particularly notable: this receptor class is the target of clonidine (used for ADHD and anxiety) and some antihypertensives, suggesting CBG may have mechanisms relevant to conditions where that pathway matters.
For most of CBG's history, what researchers knew came from animal studies and in vitro work. That changed in 2024 with the publication of the first double-blind, placebo-controlled human trial of isolated CBG.
Conducted at Washington State University and published in Scientific Reports (Cuttler et al., 2024), the study enrolled 34 healthy adult cannabis users in a crossover design. Participants ingested either 20mg of hemp-derived CBG or a placebo, then rated their anxiety, stress, mood, and potential impairment at three timepoints after ingestion. The results: CBG produced statistically significant reductions in anxiety at 20, 45, and 60 minutes compared to placebo, and reduced stress ratings at the first timepoint. Crucially, it did so without detectable intoxication, cognitive slowing, or significant side effects -- and verbal memory performance actually improved compared to placebo.
The lead researcher, Dr. Carrie Cuttler, was explicit about the limitations: the study involved experienced cannabis users (who may respond differently than naive users), used a relatively modest dose, was conducted remotely via Zoom (without physiological measures like cortisol or heart rate), and needs replication before strong conclusions can be drawn. A follow-up trial with physiological measures is in design.
What the trial does establish is a proof-of-concept: CBG can produce measurable anxiolytic effects in humans at a dose that doesn't impair function. Whether this holds across populations, doses, and conditions -- and what the mechanism is in humans specifically -- remains to be determined.
The human trial is a single data point in a much broader preclinical literature. Several areas have produced notable results:
Inflammatory bowel disease: A widely-cited 2013 preclinical study (Borrelli et al., 2013, Biochemical Pharmacology) found CBG reduced markers of inflammation and intestinal damage in a mouse model of colitis, working partly through CB2 receptors. This is one of the more replicated preclinical findings in the CBG literature.
Intraocular pressure: CBG has shown vasodilatory effects and reduced intraocular pressure in animal models, raising interest in its potential relevance to glaucoma management -- a condition where the endocannabinoid system is known to play a role.
Antibacterial activity: CBG has demonstrated activity against methicillin-resistant Staphylococcus aureus (MRSA) in laboratory studies. This research is early-stage, and "works in a lab dish" is a long way from a clinical application, but it adds to CBG's profile as pharmacologically interesting beyond the cannabinoid system.
Neuroprotection: Preclinical models have suggested CBG may have neuroprotective effects relevant to neurodegenerative conditions, though this research is early and primarily in animal models.
The consistent caveat across all of this: animal and in vitro evidence has not yet been translated into human clinical trials for most of these applications.
A registered clinical trial (NCT05743985) is currently examining the efficacy and safety of hemp-derived full-spectrum CBG in healthy adults -- one of the first studies to look at real-world CBG products (rather than isolated compounds) in human participants. The trial is notable for also investigating potential toxicological hazards, not just efficacy, which is appropriate given how quickly CBG products have entered the market ahead of clinical validation.
This mirrors the arc CBD went through -- widespread commercial use before clinical evidence caught up -- and represents the same opportunity: CBG products are already on shelves, and the research infrastructure to evaluate them is still building.
Given that many people encounter CBG as an add-on or alternative to CBD, a few direct comparisons are worth making clearly.
The most important difference is the evidence base. CBD has multiple completed human clinical trials, an FDA-approved pharmaceutical form (Epidiolex, for seizures), and a well-characterized safety profile in humans. CBG has one double-blind human trial and a substantial but largely preclinical literature. These are not equivalent starting points.
Both are non-intoxicating. Both interact with the endocannabinoid system. But CBG's additional receptor interactions (5-HT1A, alpha-2) mean its pharmacology genuinely differs from CBD's -- it's not a substitute or upgrade, it's a different compound with a different profile that happens to be produced in the same plant.
Will CBG get me high? No. Like CBD, CBG is non-intoxicating and does not produce the psychoactive effects associated with THC. The 2024 human trial specifically tested for impairment and found none.
Is CBG legal? Hemp-derived CBG (from plants with less than 0.3% THC) is legal under the 2018 Farm Bill in the US, similar to hemp-derived CBD. Cannabis-derived CBG follows the same state-by-state rules as other cannabis products.
Why is CBG more expensive than CBD? Because mature cannabis plants convert most of their CBGA into other cannabinoids, producing high-CBG material requires earlier harvests or specialized cultivars -- both of which cost more to produce.
Is there any evidence CBG helps with specific conditions? As of 2025, the evidence base for specific conditions is mostly preclinical. The one human trial demonstrating benefit was for acute anxiety in healthy adults. Claims about IBD, cancer, or other conditions in humans are ahead of the available clinical evidence.
Can I take CBG and CBD together? There's no established evidence that the combination is harmful, and some rationale (based on their different receptor targets) that they might be complementary. But "no known harm" and "proven benefit" are different things -- this hasn't been formally tested in humans.
CBG has arguably the most scientifically interesting profile of any cannabinoid currently gaining mainstream attention. Its precursor role in cannabinoid biosynthesis is unique, its receptor interactions extend beyond the CB1/CB2 system in ways that make it pharmacologically distinct from CBD, and the 2024 WSU trial provides the first human evidence that it produces meaningful anxiolytic effects without impairment. What it doesn't yet have is a validated clinical application -- the preclinical evidence is promising across several areas (IBD, glaucoma, antibacterial activity), but none of those have been confirmed in human trials. CBG is at the same stage CBD was roughly a decade ago: enough legitimate science to justify serious attention, not yet enough to justify the product claims currently surrounding it.
This article is for informational purposes only and does not constitute medical advice.
Last updated: June 2026 | Based on: 1 double-blind placebo-controlled human trial, 2 comprehensive reviews (2024), 1 registered clinical trial, and preclinical data from peer-reviewed literature (2013--2024)